Trial Profile
A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary)
- Indications Menstrual migraine
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Jun 2012 Actual patient number changed from 311 to 320 according to ClinicalTrials.gov.
- 16 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 07 Jun 2007 Results have been reported.